The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report

Liver International

Volumn 30, Issue 3, 2010, Pages 342-355

  Antaki, Nabil ^a   Craxi, Antonio ^b   Kamal, Sanaa ^c   Moucari, Rami ^d   Van der Merwe, Schalk ^e   Haffar, Samir ^f   Gadano, Adrian ^g   Zein, Nizar ^h   Lai, Ching Lung ⁱ   Pawlotsky, Jean Michel ^j   Heathcote, E Jenny ^k   Dusheiko, Geoffrey ^l   Marcellin, Patrick ^d  

^a Saint Louis Hospital   (Syrian Arab Republic)

^b UNIVERSITY OF PALERMO   (Italy)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d BEAUJON HOSPITAL   (France)

^e UNIVERSITY OF PRETORIA   (South Africa)

^f Department of Gastroenterology   (Syrian Arab Republic)

^g HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF HONG KONG   (Hong Kong)

^j HENRI MONDOR HOSPITAL   (France)

^k UNIVERSITY OF TORONTO   (Canada)

^l ROYAL FREE HOSPITAL   (United Kingdom)

more..

Author keywords

Genotype 4; Genotype 5; Genotype 6; HCV

Indexed keywords

ALPHA INTERFERON; ANTISCHISTOSOMAL AGENT; INTERFERON; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AFRICA; AUSTRALIA; BELGIUM; BLOOD TRANSFUSION; CIRCUMCISION; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DELIVERY; DENTAL CARE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; EGYPT; EUROPE; EXCISION; FRANCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HONG KONG; HUMAN; IATROGENIC DISEASE; IMMIGRANT; INSULIN RESISTANCE; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; MIDDLE EAST; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; REVIEW; SCAR FORMATION; SOUTH AFRICA; SOUTHEAST ASIA; SPAIN; SYRIAN ARAB REPUBLIC; THAILAND; TRADITIONAL MEDICINE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIET NAM; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; WESTERN HEMISPHERE; WOUND CARE;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PREVALENCE;

EID: 77950624760     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02188.x     Document Type: Review

References (129)

1. Simmonds P, Bukh J, Combet C. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-73.
2. Tokita H, Okamoto H, Iizuka H. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996, 77:293-301.
3. Tokita H, Okamoto H, Luengrojanakul P. Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol 1995, 76:2329-35.
4. Tokita H, Okamoto H, Tsuda F. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci USA 1994, 91:11022-6.
5. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995, 171:1607-10.
6. http://www.who.int/mediacentre/factsheets/fs164/en/print.html, World Health Organization., Hepatitis C. WHO fact sheet 164. Available at, (accessed 21 January 2009)
7. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005, 3((Suppl. 2)):S97-101.
8. Ohno T, Mizokami M, Tibbs CJ. New genotype of hepatitis C virus in South Africa. J Med Virol 1994, 42:409-13.
9. Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995, 33:1679-81.
10. Zhang YY, Lok AS, Chan DT, Widell A. Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China. J Clin Microbiol 1995, 33:2931-4.
11. Prescott LE, Simmonds P, Lai CL. Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. J Med Virol 1996, 50:168-75.
12. Wong DA, Tong LK, Lim W. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur J Epidemiol 1998, 14:421-6.
13. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002, 36:1259-65.
14. http://www.mohp.gov.eg/Main.asp, Egyptian Ministry of Health., Egyptian Ministry of Health Annual Report: 2007. Available at, (accessed 10 January 2009)
15. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008, 47:1371-83.
16. Antaki N, Haddad M, Kebbewar K. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect 2008, 17:1-6.
17. Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotype/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Med J 2003, 24:S87-91.
18. Al-Kubaisy WA, Niazi AD, Kubba K. History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women. East Mediterr Health J 2002, 8:239-44.
19. Keyvani H, Alizadeh AHM, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res 2007, 37:101-3.
20. Bdour S. Hepatitis C virus infection in Jordanian hemodialysis units: serological diagnosis and genotyping. J Med Microbiol 2002, 51:700-4.
21. Sharara AI, Ramia S, Ramlawi F. Genotypes of hepatitis C virus (HCV) among Lebanese patients: comparison of data with that from other middle Eastern countries. Epidemiol Infect 2007, 135:427-32.
22. Zein NN, Rakela J, Krawitt EL. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity and response to interferon therapy. Ann Intern Med 1996, 125:634-9.
23. Alter MJ, Kruszon-Moran D, Nainan OV. The prevalence of hepatitis C virus infection in the United States. 1998 through 1994. N Engl J Med 1999, 341:556-62.
24. Elkashab M, Lee SS, Eiloart S, Marotta P. Characteristics and outcome of treatment with peginterferon alfa-2a (PEGASYS) plus ribavirin (RBV) in patients with HCV genotype 4, 5, or 6 infection: analysis of the Canadian Pegasys Expanded Access Program (EAP). Can J Gastrol 2007, 21:80A. for the Canadian PEGAYS Study Group.
25. SistemaSistema Nacional de Vigilancia Epidemiológica (Si.Na.VE) de la Dir de Epidemiología del Ministerio de Salud y Ambiente de la Nación (MA)
26. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 2000, 75:17-28. World Health Organization.
27. Valdespinto JL, Olaiz G, Conde C. Reto de Hepatitis C. Resumen de cifras para tomadores de decisiones. Instituto Nacional de Salud Pública 2005, Mexico, Centro de Información para Decisiones en salud
28. Payan C, Roudot-Thoraval F, Marcellin P. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J Viral Hepat 2005, 12:405-13.
29. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48:148-62.
30. Katsoulidou A, Sypsa V, Tassopoulos NC. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006, 13:19-27.
31. Haushofer AC, Kopty C, Hauer R, Brunner H, Halbmayer WM. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol 2001, 20:41-7.
32. Cicciarello S, Borgia G, Crowell J. Prevalence of hepatitis C virus genotypes in southern Italy. Eur J Epidemiol 1997, 13:49-54.
33. Gérard C, Delwaide J, Vaira D. Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. J Med Virol 2005, 76:503-10.
34. Ross RS, Viazov S, Renzing-Köhler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 2000, 60:122-5.
35. Abacioglu YH, Davidson F, Tuncer S. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995, 2:297-301.
36. Sánchez-Quijano A, Abad MA, Torronteras R. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997, 27:25-9.
37. Dal Molin G, Ansaldi F, Biagi C. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002, 68:352-6.
38. de Vries MJ, te Rijdt B, van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med 2006, 64:109-13.
39. Tucker TJ, Voigt M, Bird A. Hepatitis C virus infection rate in volunteer blood donors from the Western Cape comparison of screening tests and PCR. S Afr Med J 1997, 87:603-5.
40. Henquell C, Cartau C, Abergel A. High prevalence of hepatitis C virus type 5 in Central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004, 42:3030-5.
41. Verbeeck J, Maes P, Lemey P. Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 2006, 80:4220-6.
42. Jover R, Pérez-Serra J, de Vera F. Infection by genotype 5a of HCV in a district of southeast Spain. Am J Gastroenterol 2001, 96:3042-3.
43. Ansaldi F, Bruzzone B, Salmaso S. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005, 76:327-32.
44. Zhao W, Xu DP, Xue R. Uneven geographic distribution of HCV genotypes across China. Hepatol Int 2009, 3:77.
45. Tan Y, Wei QH, Chen LJ. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. PLoS One 2008, 3:e3608.
46. Peng JS, Wang X, Liu MQ. Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China. Virus Res 2008, 135:191-6.
47. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N. Various subtypes of hepatitis C virus genotype 6 found in central Thailand. Hepatol Int 2009, 3:76.
48. Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005, 9:411-26.
49. Nainan OV, Alter MJ, Kruszon-Moran D. Hepatitis C genotypes and viral concentrations in participants of general population survey in the United States. Gastroenterology 2006, 131:478-84.
50. Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of hepatitis C infection in Asian Americans. Am J Gastroenterol 2006, 101:2737-43.
51. Frank C, Mohamed MK, Strickland GT. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355:887-912.
52. Rao MR, Naficy AB, Darwish MA. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002, 2:29.
53. El Katsha S, Labeeb S, Watts S, Younis A. Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. East Mediterr Health J 2006, 12:758-67.
54. Inhorn MC. Urban Egyptian women in the informal health care sector. Middle Eastern women and the invisible economy 1998, Lobban RA. In, ed, Gainesville, FL, University Press of Florida
55. Egypt demographic and health survey, 1995. Chapter 13 1996, National Population Council, Egypt & Macro International Inc., Calverton, MD, National Population Council, Egypt & Macro International Inc.
56. Stoszek SK, Abdel-Hamid M, Narooz S. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006, 100:102-7.
57. Talaat M, el-Oun S, Kandeel A. Overview of injection practices in two governorates in Egypt. Trop Med Int Health 2003, 8:234-41.
58. Lohiniva AL, Talaat M, Bodenschatz C. Therapeutic injections in the context of Egyptian culture. Promot Educ 2005, 12:13-8.
59. Talaat M, Kandeel A, El-Shoubary W. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. Am J Infect Control 2003, 31:469-74.
60. Bassily S, Hyams K, Fouad R, Samaan M, Hibbs R. A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. Am J Trop Med Hyg 1995, 52:503-5.
61. Magder LS, Fix AD, Mikhail NN. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol 2005, 34:160-5.
62. Kamal SM, Amin A, Madwar M. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004, 78:12252-8.
63. Mudawi HM, Smith HM, Fletcher IA, Fedail SS. Prevalence and common genotypes of HCV infection in Sudanese patients with hepatosplenic schistosomiasis. J Med Virol 2007, 79:1322-4.
64. Xu L-Z, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994, 75:2393-8.
65. Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 2003, 84:2333-41.
66. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15years on. J Gen Virol 2004, 85:3173-88.
67. Muasya T, Lore W, Yano K. Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya. East Afr Med J 2008, 85:318-25.
68. Njouom R, Nerrienet E, Dubois M. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol 2007, 7:361-7.
69. Nicot F, Legrand-Abravanel F, Sandres-Saune K. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005, 86:107-14.
70. Delwaide J, Reenaers C, Gerard C. HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin. Eur J Gastroenterol Hepatol 2006, 18:707-12.
71. Moucari R, Asselah T, Cazals-Hatem D. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level and liver fibrosis. Gastroenterology 2008, 134:416-23.
72. Ferenci P, Laferl H, Scherzer TM. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008, 135:451-8.
73. Diamantis I, Vafiadis I, Voskaridou E. Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. Eur J Gastroenterol Hepatol 1998, 10:75-9.
74. Guadagnino V, Stroffolini T, Rapicetta M. Prevalence, risk factor and genotype distribution of HCV infection in the general population: a community-based survey in Southern Italy. Hepatology 1997, 26:1006-11.
75. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999, 6:435-43.
76. Roulot D, Bourcier V. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007, 14:460-7. Observational VHC4 Study Group.
77. Moucari R, Ripault MP, Martinot-Peignoux M. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009, 58:1662-9.
78. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004, 38:68-71.
79. Legrand-Abravanel F, Sandres-Sauné K, Barange K. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004, 189:1397-400.
80. Bonny C, Fontaine H, Poynard T. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006, 24:593-600.
81. Delwaide J, Gerard C, Reenaers C. Hepatitis C virus genotype 5 in Southern Belgium: epidemiological characteristics and response to therapy. Digest Dis Sci 2005, 50:2348-51.
82. Bernier L, Willems B, Delage G, Murphy DG. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Med Microbiol 1996, 34:2815-8.
83. Levi JE, Takaoka DT, Garrini RH. Three cases of infection with hepatitis C virus genotype 5 among Brazilian hepatitis patients. J Med Microbiol 2002, 40:2645-7.
84. Abergel A, Ughetto S, Dubost S. The epidemiology and virology of hepatitis C virus genotype 5 in central France. Aliment Pharmacol Ther 2007, 26:1437-46.
85. Seeff L. Natural history of chronic hepatitis C. Hepatology 2002, 36((Suppl. 1)):S35-46.
86. Kamal SM, Rasenack JW, Bianchi L. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001, 121:646-56.
87. Kamal SM, Ismail A, Graham CS. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus specific T cell response kinetics. Hepatology 2004, 39:1721-31.
88. Kamal SM, Turner B, He Q. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006, 43:771-9.
89. Kamal SM, Graham CS, He Q. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4_ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004, 189:1140-50.
90. Esmat G, Metwally M, Zalata KR. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007, 46:620-7.
91. Soriano V, Mocroft A. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198:1337-44. EuroSIDA Study Group.
92. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. NIH Pub. No. 06-5873 2006, Freedman LSEdwards BKRies LAGYoung JL. eds, Bethesda, MD, National Cancer Institute
93. http://www.nci.edu.eg, National Cancer Registry of Egypt., Magnitude of hepatocellular carcinoma in Egypt. Available at, (accessed 3 January 2009)
94. Abdel-Hamid M, El-Daly M, Molnegren V. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007, 88((Part 5)):1526-31.
95. Ezzat S, Abdel-Hamid M, Eissa SA. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005, 208:329-39.
96. Nieuwoudt M, Arazi A, Neumann A, Van der Merwe SW. Viral kinetics of HCV genotype 5 in South Africa patients treated with pegylated-interferon-alpha and ribavirin. Hepatology 2007, 46:367A.
97. Seto WK, Lai CL, Fung J. Interim analysis of the natural history of chronic hepatitis C genotype 1 and 6. Hepatology 2008, 48((Suppl. 1)):1102A.
98. Kamal SM, Fouly AE, Kamel RR. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006, 130:632-8.
99. Kamal SM, Moustafa KN, Chen J. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006, 43:923-31.
100. Legrand-Abravanel F, Nicot F, Boulestin A. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005, 77:66-9.
101. Soriano V, Núñez M, Sánchez-Conde M. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antiviral Ther 2005, 10:167-70.
102. Martín-Carbonero L, Puoti M, García-Samaniego J. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hepat 2008, 15:710-5.
103. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000, 132:845-6.
104. Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000, 32:172-4.
105. Esmat GH, Abouzied A, Abdel-Hamid M. Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin. Hepatology 2003, 38((Suppl.)):314A-5A. (abstract)
106. Shobokshi A, Serebour PE, Skakni L. Combination therapy of peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003, 38((Suppl.)):636A. (abstract)
107. Hasan F, Asker H, Al-Khaldi J. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004, 99:1733-7.
108. Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004, 140:72-3.
109. Alfaleh FZ, Hadad Q, Khuroo MS. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004, 24:568-74.
110. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004, 20:931-8.
111. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 2002, 35:82-5.
112. Kamal SM, El Tawil AA, Nakano T. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005, 54:858-66.
113. El-Zayadi AR, Attia M, Barakat EM. Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-a2b/ribavirin or induction-dose interferon-a2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005, 100:2447-52.
114. Derbala MF, Al Kaabi SR, El Dweik NZ. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006, 12:5692-8.
115. Kamal S, Kamary S, Shardell M. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007, 46:1732-40.
116. Jessner W, Gschwantler M, Formann E. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection. Antivir Ther 2008, 13:581-9.
117. Al Ashgar H, Helmy A, Khan MQ. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009, 29:4-14.
118. Trapero-Marugan M, Moreno-Monteagudo JA, Garcia-Buey L. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a Spanish center. J Chemother 2007, 19:423-7.
119. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009, 136:856-62.
120. Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009, 29((Suppl. 1)):39-48. (review)
121. Jensen DM, Morgan TR, Marcellin P. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-60.
122. D'Heygere F, George C, Nevens F. Patients infected with HCV-5 present the same response rate as patients infected with HCV-1: results from the Belgian randomized trial for naïve and relapsers (BERNAR-1) [abstract]. J Hepatol 2005, 42:203A.
123. Antaki N, Hermes A, Hadad M. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008, 15:383-6.
124. Hui CK, Yuen MF, Sablon E. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003, 187:1071-4.
125. Fung J, Lai CL, Hung I. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008, 198:808-12.
126. Nguyen MH, Trinh HN, Garcia R. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008, 103:1131-5.
127. Li F, Ng TL, Tai LF. High response rate of combination therapy of pegylated interferon and ribavirin in treating chronic hepatitis C with genotype 6A in Hong Kong Chinese. Hepatol Int 2009, 3:164.
128. PThi TT, Ho TD. Pegylated interferon alfa-2a plus ribavirin in chronic hepatitis C patient with genotype 6. Hepatol Int 2009, 3:49.
129. Antaki N, Marcellin P. What is the safe duration of therapy for patients infected with HCV genotype 6? Nat Clin Pract Gastroenterol Hepatol 2009, 6:78-9.